#### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

plicants: J. Henslee and P.N. Friedman

Serial No.: 10/816,326

Filed: April 1, 2004

For: REAGENTS AND METHODS USEFUL FOR DETECTING DISEASES OF THE

**BREAST** 

Attorney Docket No.: 5972.US.D3

Group Art Unit: 1645

Examiner: (not yet assigned)

Certificate of Mailing under 37 CFR §1.8(a): I hereby certify that this paper (along with any paper

referred to as being attached or enclosed) is being deposited with the United States Postal Service with sufficient postage as First Class Mail addressed to as

follows:

**MS Missing Parts** 

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Date of Deposit: 8/17/04

Kimberly A. Iorio

### TRANSMITTAL LETTER

MS Missing Parts Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Enclosed herewith for the patent application identified above entitled REAGENTS AND METHODS USEFUL FOR DETECTING DISEASES OF THE BREAST are the following:

- Response to Notice to Comply with Requirements for Patent Applications;
   Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures (1 Page) in duplicate;
- 2. Copy of Notice To Comply (2 Pages);
- 3. Request to Use Computer Readable Form from a Priority Application (1 Page);
- 4. Statement to Support the Filings and Submissions in Accordance with 37 CFR §1,821-1.825 (1 Page);
- 5. Paper Form Sequence Listing (3 Pages); and
- 6. Return Receipt Postcard.

The Commissioner is hereby authorized to charge any additional Filing Fees required under 37 CFR §1.16, as well as any patent application processing fees under 37 CFR §1.17 associated with this communication for which full payment had not been tendered, to Deposit Account No. 01-0025. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

J. Henslee, et al.

ABBOTT LABORATORIES Customer No.: 23492

Telephone: (847) 935-1729 Facsimile: (847) 938-2623

Cheryl L. Becker Registration No. 35,441

Attorney for Applicants



UNITED STATES DEPARTMENT OF COMMERC UNITED STATES DEFARIMENT OF COMMI United States Patent and Tradesmark Offices Address COMMISSIONER FOR PATENTS P.C. DOR 1450 Alexandra, Vriginia 22313-1450 www.unphugov

APPLICATION NUMBER '

FILING OR 371 (c) DATE

FIRST NAMED APPLICANT

ATTORNEY DOCKET NUMBER

10/816,326

04/01/2004

Jerry Henslee

5972.US.D3

**CONFIRMATION NO. 9145 FORMALITIES LETTER** 

\*OC000000012968667\*

23492 STEVEN F. WEINSTOCK ABBOTT LABORATORIES 100 ABBOTT PARK ROAD **DEPT. 377/AP6A** ABBOTT PARK, IL 60064-6008

Date Mailed: 06/17/2004

#### NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

` Filing Date Granted

Applicant is given TWO MONTHS FROM THE DATE OF THIS NOTICE within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

• This application clearly fails to comply with the requirements of 37 CFR. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing", an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment directing its entry into the application. Applicant must also provide a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase Patentin Software, call (703) 306-2600
- For Patentin Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

Replies should be mailed to:

Mail Stop Missing Parts

Commissioner for Patents

## P.O. Box 1450 Alexandria VA 22313-1450

# A copy of this notice MUST be returned with the reply.

Customer Service Center
Initial Patent Examination Division (703) 308-1202
PART 3 - OFFICE COPY



pplicants: J. Henslee and P.N. Friedman

Serial No.: 10/816,326

Filed: April 1, 2004

For: REAGENTS AND METHODS USEFUL FOR DETECTING DISEASES

OF THE BREAST

Attorney Docket No.: 5972.US.D3

Group Art Unit: 1645

Examiner: (not yet assigned)

Certificate of Mailing under 37 CFR §1.8(a):

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service with sufficient postage as First Class Mail addressed to as follows:

MS Missing Parts Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Date of Deposit: 8/17/04

Kimberly A. Iorio

# RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

MS Missing Parts Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

In response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, mailed on June 17, 2004, in the patent application identified above, Applicants submit herewith a Request To Use Computer Readable Form From A Priority Application, a paper copy of the Sequence Listing, and a Statement To Support The Filings and Submissions in Accordance with 37 C.F.R. §1.821-1.825.

The Commissioner is hereby authorized to charge the payment of any patent application processing fees under 37 CFR 1.17 concerning this transaction, or to credit any overpayment, to Deposit Account No. 01-0025. A duplicate copy of this sheet is attached.

Respectfully submitted,

J. Henslee and P.N. Friedman

**ABBOTT LABORATORIES** 

Customer No.: 23492

Telephone: (847) 935-1729 Facsimile: (847) 938-2623

Cheryl L. Becker

Registration No. 35,441 Attorney for Applicants